123 related articles for article (PubMed ID: 38490329)
21. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
22. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
[TBL] [Abstract][Full Text] [Related]
23. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
24. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
25. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
26. Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer.
Saraç H; Morova T; Pires E; McCullagh J; Kaplan A; Cingöz A; Bagci-Onder T; Önder T; Kawamura A; Lack NA
Oncogene; 2020 Mar; 39(10):2187-2201. PubMed ID: 31822799
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
[TBL] [Abstract][Full Text] [Related]
28. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
29. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
Li Y; Shi H; Zhao Z; Xu M
BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
[TBL] [Abstract][Full Text] [Related]
30. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
31. Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer.
Orea MJ; Angulo JC; González-Corpas A; Echegaray D; Marvá M; Lobo MVT; Colás B; Ropero S
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614243
[TBL] [Abstract][Full Text] [Related]
32. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
33. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
Cai Z; Wu Y; Li Y; Ren J; Wang L
Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
[TBL] [Abstract][Full Text] [Related]
34. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
35. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
36. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
37. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
Sun T; Wang X; He HH; Sweeney CJ; Liu SX; Brown M; Balk S; Lee GS; Kantoff PW
Oncogene; 2014 May; 33(21):2790-800. PubMed ID: 23770851
[TBL] [Abstract][Full Text] [Related]
38. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
39. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
40. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]